Miriam E. Tucker

May 18, 2026 The FDA has approved a dosing update for burosumab -twza (Crysvita, Kyowa Kirin) to allow for increased dose and frequency when needed in adults with X-linked hypophosphatemia (XLH).

A large database study shows lower risk for major adverse cardiovascular events and end-stage kidney disease, with no increase in adverse events.

A survey found that clinicians are not discussing genetic testing with 80% of patients with kidney disease who meet established clinical criteria.

New receptor agonist combinations, a once-monthly GLP-1, and full retatrutide data are all on the agenda, along with a huge spectrum of other diabetes-related content.

The FDA first approved MannKind’s Afrezza for adults with diabetes in 2014.

No changes in diabetic retinopathy status occurred in high-risk people with type 2 diabetes taking tirzepatide when compared with dulaglutide.

Study findings suggest that a liver-targeted formulation of fast-acting insulin may reduce the risk for hypoglycemia in patients with type 1 diabetes.

The glucagon receptor/GLP-1 receptor dual agonist reduces weight, visceral fat, and liver fat.

Phase 3 trials of the oral nonpeptide show glycemic and weight benefit when added to glargine and compared with dapagliflozin and oral semaglutide, but with somewhat lower tolerability.

The US FDA extended the age of use for Dexcom’s Stelo down to 2 years.